NSEAcquisition28 Sept 2026 · 28 Sept 2026, 09:20 pm
Acquisition
Indoco Remedies Limited · INDOCO
✦ AI SummaryJoint Venture
Indoco Remedies Limited has informed the Exchange about the incorporation of a Wholly Owned subsidiary, Warren Lifesciences Private Limited, under the provisions of the Companies Act, 2013.
Analysis Scores
Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Indoco Remedies Limited has informed the Exchange about the incorporation of Wholly Owned subsidiary of the Company in the name and style of "Warren Lifesciences Private Limited .
Attachments (1)
📄pdf
Download →
INDOCO_28092026211330_Intimation_Incorporation_Subsidiary_-.pdf
View document text
Date: 28th September, 2026
To To
The Listing Department The Listing Department
National Stock Exchange of India Limited Bombay Stock Exchange Limited
Exchange Plaza, Floor 25, P. J. Towers,
Bandra – Kurla Complex Dalal Street,
Bandra (East) Mumbai – 400 001
Mumbai – 400 051 Stock Code : 532612
Stock Code : INDOCO
Dear Sir/Madam,
Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 – Incorporation of Wholly Owned Subsidiary
We refer to our letter dated 18th September, 2026 wherein we informed about the
Committee of Executive Director’s approval for the incorporation of the wholly owned
subsidiary of the Company. In continuation to the aforesaid letter and pursuant to
Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015, please note that the Company received intimation today that the Wholly Owned
Subsidiary of the Company in the name and style of “Warren Lifesciences Private Limited”
has been incorporated on 26th September, 2026 under the provisions of the Companies Act,
2013.
Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-
POD2/I/3762/2026 dated 30th January, 2026 are enclosed as Annexure A.
You are requested to kindly take the same on record.
Thanking you,
Yours faithfully,
For Indoco Remedies Limited
Ramanathan Hariharan
Company Secretary & Head Legal
Annexure A
Sr. No. Particulars Details
1 Name of the target entity, details in Name of the Target Entity
brief such as size, turnover etc.; Warren Lifesciences Private Limited (WLPL)
WLPL has authorised share capital of Rs.
1,00,000 divided into 10,000 equity shares
of Rs. 10/- each.
Size/Turnover:
Not applicable as the Company is newly
incorporated on 26th September, 2026
2 Whether the acquisition would fall Being a wholly owned subsidiary, WLPL is a
within related party transaction(s) related party of Indoco Remedies Limited.
and whether the promoter/
promoter group/ group companies
have any interest in the entity being
acquired? If yes, nature of interest
and details thereof and whether the
same is done at “arm’s length”;
3 Industry to which the entity being Pharmaceutical Sector
acquired belongs;
4 Objects and impact of acquisition WLPL is incorporated with the object to
(including but not limited to, manufacture, develop, sell etc.
disclosure of reasons for acquisition pharmaceutical products including but not
of target entity, if its business is limited to active pharmaceutical
outside the main line of business of ingredients, finished formulations, key
the listed entity); starting materials.
5 Brief details of any governmental or Not Applicable as this intimation is about
regulatory approvals required for incorporation
the acquisition;
6 Indicative time period for Not Applicable as this intimation is about
completion of the acquisition; incorporation
7 Consideration - whether cash Subscription of shares in WLPL will be by
consideration or share swap or any way of cash consideration.
other form and details of the same
8 Cost of acquisition and/or the price 10,000 equity shares of WLPL will be
at which the shares are acquired; subscribed at face value of Rs. 10 per
share.
9 Percentage of shareholding / control WLPL is incorporated with the authorised
acquired and / or number of shares share capital of Rs. 1,00,000 divided into
acquired; 10,000 equity shares of Rs. 10/- each.
The entire paid-up share capital (i.e. 100%
of the shareholding) of WLPL will be held
by Indoco Remedies Limited.
10 Brief background about the entity Terms of products/line of business:
acquired in terms of products/line of WLPL will manufacture, develop, sell etc.
business acquired, date of pharmaceutical products including but not
incorporation, history of last 3 years limited to active pharmaceutical
turnover, country in which the ingredients, finished formulations, key
acquired entity has presence and starting materials.
any other significant information (in
brief); Date of incorporation:
WLPL is incorporated in India and is
registered with the Registrar of
Companies, Mumbai, Maharashtra on 26th
September, 2026 and is yet to commence
its business operations.
History of last 3 years turnover:
Not Applicable as newly incorporated
company.
Country in which the acquired entity has
presence:
India